Charles River Laboratories International (CRL) reaffirmed its fiscal 2026 guidance for non-GAAP earnings at the upper end of $11.15 to $11.45 per share and for revenue growth at the upper end of 0% to 1%, the company said Thursday.
Analysts polled by FactSet expect adjusted EPS of $11.33.
For fiscal 2027 to 2030, the company expects low-double-digit compound annual EPS growth rate and revenue compound annual revenue growth of 5% to 7%, it said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.